[go: up one dir, main page]

MX2009011416A - Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. - Google Patents

Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.

Info

Publication number
MX2009011416A
MX2009011416A MX2009011416A MX2009011416A MX2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
zoles
thia
dia
compounds
Prior art date
Application number
MX2009011416A
Other languages
English (en)
Inventor
Gregor James Macdonald
Jose Manuel Bartolome-Nebreda
Michiel Luc Maria Van Gool
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009011416A publication Critical patent/MX2009011416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a [1-(bencil)-piperidin-4-iI]-([1 ,3,4]tiadiazol-2-iI)-amina y derivados de [1-(bencil)-piperidin-4- il]-(tiazol-2-il)-amina de fórmula (I) que son antagonistas del receptor de dopamina 2 de disociación rápida, los procesos para preparar estos compuestos, las composiciones farmacéuticas que comprenden estos compuestos como un ingrediente activo; los compuestos se usan como medicamentos para tratar o prevenir trastornos del sistema nervioso central, por ejemplo esquizofrenia, al ejercer un efecto antipsicótico sin efectos secundarios motores.
MX2009011416A 2007-04-23 2008-04-18 Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. MX2009011416A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07106706 2007-04-23
PCT/EP2008/054732 WO2008128996A1 (en) 2007-04-23 2008-04-18 Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists

Publications (1)

Publication Number Publication Date
MX2009011416A true MX2009011416A (es) 2009-11-05

Family

ID=38476031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011416A MX2009011416A (es) 2007-04-23 2008-04-18 Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.

Country Status (15)

Country Link
US (1) US8933101B2 (es)
EP (1) EP2148879B1 (es)
JP (1) JP5431306B2 (es)
KR (1) KR101506156B1 (es)
CN (1) CN101663299A (es)
AR (1) AR066242A1 (es)
AU (1) AU2008240729B2 (es)
CA (1) CA2682671C (es)
CL (1) CL2008001158A1 (es)
ES (1) ES2400710T3 (es)
IL (1) IL201661A (es)
MX (1) MX2009011416A (es)
RU (1) RU2489431C2 (es)
TW (1) TWI423969B (es)
WO (1) WO2008128996A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CN101663292A (zh) * 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物
KR20100016498A (ko) * 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 피리딘 유도체
BRPI0915834A2 (pt) * 2008-07-03 2015-11-03 Janssen Pharmaceutica Nv 6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6
AU2009275887B2 (en) * 2008-07-31 2013-06-20 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
KR20180002676A (ko) * 2015-04-07 2018-01-08 엘라 파마 리미티드 Cathepsin c 및/또는 cela1 및/또는 cela3a 및/또는 그와 관련된 구조적 효소를 타겟으로 하여 세포 또는 조직의 감염을 치료 및/또는 예방하기위한 조성물

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933823A (en) * 1971-03-29 1976-01-20 E. R. Squibb & Sons, Inc. Isoxazolopyridine ketone derivatives
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) * 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
ES2133714T3 (es) 1993-12-28 1999-09-16 Upjohn Co Compuestos heterociclicos para el tratamiento de trastornos del snc y cardiovasculares.
DE4425145A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
TW406075B (en) 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
IL133960A0 (en) 1997-08-15 2001-04-30 Pfizer Prod Inc 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
EA005974B1 (ru) 2001-02-23 2005-08-25 Мерк Энд Ко., Инк. N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
WO2003035645A1 (fr) 2001-10-09 2003-05-01 Kyorin Pharmaceutical Co., Ltd. Nouvelles 4-(2-furoyl)aminopiperidines, intermediaires utilises dans la synthese de ces dernieres, leur procede de production et leur utilisation medicale
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
US7812035B2 (en) * 2001-12-11 2010-10-12 Sepracor Inc. 4-substituted piperidines, and methods of use thereof
EP1467981A1 (en) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
IL162859A0 (en) 2002-02-05 2005-11-20 Novo Nordisk As Novel aryl-and heteroarylpiperazines
WO2003072548A1 (en) 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Pyridyl sulfone derivatives as 5-ht receptor antagonists
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
ATE551053T1 (de) * 2002-09-26 2012-04-15 Mandom Corp Antiseptische bakterizide, und kosmetika, arzneimittel und lebensmittel, die die antiseptischen bakterizide enthalten
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
US8716214B2 (en) 2003-05-07 2014-05-06 Otc Gmbh Compositions for the targetted release of fragrances and aromas
BRPI0410239A (pt) 2003-05-08 2006-05-16 Kyorin Seiyaku Kk composto de 4-(2-furoil)aminopiperidina e medicamento
PL1648882T3 (pl) * 2003-06-04 2008-12-31 Merck & Co Inc 3-Fluoro-piperydyny jako antagoniści NMDA/NR2B
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
KR20060054392A (ko) 2003-07-29 2006-05-22 노보 노르디스크 에이/에스 피리다지닐-피페라진 및 히스타민 ｈ３ 수용체 리간드로서그들의 사용
AU2004261252C1 (en) * 2003-07-30 2009-09-17 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
WO2005046581A2 (en) 2003-10-24 2005-05-26 Cheng Tao M D P18 in stem cell manipulations
ATE371649T1 (de) 2004-02-10 2007-09-15 Janssen Pharmaceutica Nv Pyridazinonharnstoffe als antagonisten von a4- integrinen
WO2005090317A1 (en) 2004-03-23 2005-09-29 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
EP1742932A1 (en) 2004-04-28 2007-01-17 Pfizer Limited 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
WO2005117883A1 (en) 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1776357A1 (en) * 2004-08-09 2007-04-25 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
DK1805158T3 (en) 2004-10-29 2018-08-06 Kalypsys Inc SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
SI1824479T1 (sl) * 2004-12-08 2009-04-30 Solvay Pharm Bv Derivati fenilpiperazina s kombinacijo delnega dopamin-d2 receptorskega agonizma in inhibiranje ponovnega privzema serotonina
WO2006105993A2 (en) * 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
EP1902046B1 (en) 2005-06-20 2009-12-02 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
JO2769B1 (en) * 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
BRPI0715967A2 (pt) 2006-08-15 2013-08-06 Hoffmann La Roche compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodos para o tratamento e/ou prevenÇço de enfermidades que estço associadas com a modulaÇço de receptores de sst do subtipo 5, e uso destes compostos
US8058243B2 (en) * 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CN101663292A (zh) * 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物
KR20100016498A (ko) * 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 피리딘 유도체
EP2194983A1 (en) * 2007-09-20 2010-06-16 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
BRPI0915834A2 (pt) * 2008-07-03 2015-11-03 Janssen Pharmaceutica Nv 6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6
AU2009275887B2 (en) * 2008-07-31 2013-06-20 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists

Also Published As

Publication number Publication date
KR101506156B1 (ko) 2015-03-26
AR066242A1 (es) 2009-08-05
CL2008001158A1 (es) 2008-11-03
US8933101B2 (en) 2015-01-13
CN101663299A (zh) 2010-03-03
RU2489431C2 (ru) 2013-08-10
AU2008240729A1 (en) 2008-10-30
TW200911799A (en) 2009-03-16
JP5431306B2 (ja) 2014-03-05
AU2008240729B2 (en) 2012-08-23
US20100120860A1 (en) 2010-05-13
KR20100016090A (ko) 2010-02-12
CA2682671C (en) 2015-11-17
EP2148879A1 (en) 2010-02-03
IL201661A0 (en) 2010-05-31
JP2010525015A (ja) 2010-07-22
ES2400710T3 (es) 2013-04-11
TWI423969B (zh) 2014-01-21
WO2008128996A1 (en) 2008-10-30
EP2148879B1 (en) 2012-11-28
CA2682671A1 (en) 2008-10-30
RU2009142981A (ru) 2011-05-27
IL201661A (en) 2015-07-30

Similar Documents

Publication Publication Date Title
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
MX2009011415A (es) Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
MY145609A (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
MX2009011416A (es) Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
JO2849B1 (en) Dopamine 2 receptor antagonists are rapidly hydrolyzed
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
MX2009003958A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso.
ATE555099T1 (de) Dual wirkende benzimidazol-derivate und deren verwendung als blutdrucksenkende mittel
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
MY148772A (en) Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
EA201170256A1 (ru) Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d2 рецепторов дофамина
MY137272A (en) Imidazole derivatives
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
MX2009011414A (es) Derivados de piridina como antagonistas del receptor de dopamina 2 de disociacion rapida.
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
MXPA05013233A (es) Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato.
MY142085A (en) Imidazole derivatives

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration